Jefferies Financial Group assumed coverage on shares of Avalo Therapeutics (NASDAQ:AVTX - Free Report) in a research note issued to investors on Tuesday morning, Marketbeat reports. The brokerage issued a buy rating and a $23.00 price objective on the stock.
A number of other brokerages also recently commented on AVTX. BTIG Research started coverage on shares of Avalo Therapeutics in a research report on Thursday, December 19th. They set a "buy" rating and a $40.00 price objective for the company. HC Wainwright reissued a "neutral" rating on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Piper Sandler began coverage on shares of Avalo Therapeutics in a research report on Friday, February 28th. They issued an "overweight" rating and a $48.00 price objective for the company. Stifel Nicolaus began coverage on Avalo Therapeutics in a report on Tuesday. They issued a "buy" rating and a $36.00 price objective for the company. Finally, Wedbush reaffirmed an "outperform" rating and set a $18.00 price target on shares of Avalo Therapeutics in a report on Thursday, March 20th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, Avalo Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $33.00.
Get Our Latest Report on AVTX
Avalo Therapeutics Trading Down 3.1 %
AVTX traded down $0.27 during trading on Tuesday, reaching $8.46. The company's stock had a trading volume of 36,738 shares, compared to its average volume of 72,453. Avalo Therapeutics has a 1 year low of $5.99 and a 1 year high of $22.47. The firm has a fifty day simple moving average of $7.62 and a two-hundred day simple moving average of $9.14.
Institutional Investors Weigh In On Avalo Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of AVTX. Tower Research Capital LLC TRC increased its stake in Avalo Therapeutics by 998.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company's stock worth $31,000 after acquiring an additional 3,754 shares during the period. Marshall Wace LLP bought a new stake in Avalo Therapeutics in the fourth quarter worth approximately $114,000. Walleye Capital LLC bought a new position in Avalo Therapeutics in the fourth quarter worth approximately $145,000. Northern Trust Corp acquired a new position in shares of Avalo Therapeutics during the fourth quarter valued at about $168,000. Finally, Bank of Montreal Can bought a new stake in Avalo Therapeutics during the fourth quarter worth $446,000. 87.06% of the stock is owned by institutional investors.
About Avalo Therapeutics
(
Get Free Report)
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
Featured Stories
Before you consider Avalo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalo Therapeutics wasn't on the list.
While Avalo Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
